Drug Profile
ERB 196
Alternative Names: WAY-202196Latest Information Update: 15 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Class Small molecules
- Mechanism of Action Estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Sepsis
Most Recent Events
- 15 Sep 2011 Discontinued - Phase-I for Inflammation in USA (unspecified route)
- 15 Sep 2011 Discontinued - Preclinical for Sepsis in USA (unspecified route)
- 16 Oct 2009 Wyeth has been acquired by Pfizer